Last reviewed · How we verify
NCT06348186
Fascial Tissue Response to Manual Therapy: Implications in Long COVID-19
NA trial testing Guidebook in COVID-19 in 30 participants. Currently enrolling.
1 April 2024
Quick facts
| Lead sponsor | University of the State of Santa Catarina |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 February 2024 |
| Primary completion | 1 April 2024 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Guidebook
- Guidebook and Myofascial Reorganization® (RMF).
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
University of the State of Santa Catarina
Who can join
Adults 20 to 80, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
According to the World Health Organization (WHO), as of mid-September 2022, more than 21 million Brazilians have recovered from COVID-19. However, post-infection symptoms continue to appear months after the end of the acute infection, a syndrome called long COVID. Therefore, the aim of this study is to investigate the responses of fascia-focused manual therapy in participants with long COVID.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06348186
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other University of the State of Santa Catarina trials
Trials by the same sponsor.
- NCT07469280 — High-Intensity Progressive Inspiratory Muscle Training in Class III Obesity and Obstructive Sleep Apnea · NA · not yet recruiting
- NCT06485063 — Myofascial Reorganization on Performance, and Biomechanical, Viscoelastic, and Thermographic Properties of Athletes · NA · recruiting
- NCT05760664 — Exercises Directed To Dynamic Stiffness Of The Thoracolumbar Region And Performance Of Amateur Runners · NA · recruiting
- NCT05742542 — The Effects of High vs. Low Time Spent Near VO2max During Two Work-matched High Intensity Interval Training. · NA · completed
- NCT05409014 — Pelvic Floor Muscle Training on Urinary Incontinence Symptoms and Quality of Life in Women Who Practice Physical Exercis · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06348186 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of the State of Santa Catarina
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06348186.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing